Chemed Corporation (CHE) - Stock Analysis

Last updated: Sep 6, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Healthcare services beat-and-raise candidate: Q1 2026 revenue and adjusted EPS beat estimates, full-year guidance was raised, VITAS growth remained strong with admissions up 6.9%, and the company added a new $300M buyback authorization.

Loading chart data...

Idea window: 4/28/2026 – 5/5/2026Sector: Healthcare

AI Analyst Overview

Last Price
$514.40
Market Cap
$6.72B
1D Return
-0.80%
YTD Return
+20.70%

Loading chart data...

Valuation Metrics

P/E
25.8
P/B
8.3
P/S
2.6
EV/EBITDA
16.1
Div Yield
0.49%

Fundamental Analysis

6.0

Key Financial Insights: • Strong Cash Flow • Rising Leverage • Weakening Liquidity CHE remains highly profitable and cash-generative, but rising leverage, weaker liquidity, and richer valuation multiples warrant caution.

Profitability
LiquidityRisk

Price Behavior

4.0

Key Price Behavior Insights: • Monthly decline • Support holding • Resistance overhead Support Level: $515–$520 Resistance Level: $533; stronger at $540–$552 CHE is bearish over the last month, with support at $515–$520 and a recovery above $533 needed to improve momentum.

Bearish
Technical

Sentiment & News

5.0

Key News Insights: • Fiduciary investigations • Institutional buying • Dividend increase Chemed faces fiduciary-duty investigations despite institutional buying and a 17% dividend increase, creating mixed near-term sentiment.

LegalRisk
DividendGrowth
AI

AI Summary

6.0
Neutral

CHE is now chiefly a VITAS-driven execution investment: sustained admissions, census growth, and margin expansion could justify its premium valuation, but any slowdown—especially without a Roto-Rooter margin recovery—could compress the 25–26x earnings multiple amid rising leverage and governance scrutiny. Investors should await confirmation that VITAS operating leverage remains durable and Roto-Rooter restores incremental profitability before adding aggressively.

VITASGrowth
ValuationRisk
Execution
AI summary updated 5 days ago

Description

Chemed Corporation delivers hospice and palliative care through a multidisciplinary network of clinicians, aides, social workers, clergy and volunteers across the United States under its VITAS segment, and provides plumbing, drain, excavation and water-restoration services to residential and commercial customers via company branches, independent contractors and franchisees under its Roto-Rooter segment. The company operates these two distinct businesses from its headquarters in Cincinnati and has been incorporated since 1970.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Apr 28May 5CHEChemed Corporation
Healthcare services beat-and-raise candidate: Q1 2026 revenue and adjusted EPS beat estimates, full-year guidance was raised, VITAS growth remained strong with admissions up 6.9%, and the company added a new $300M buyback authorization.
Closed+1.5%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.